3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
16
Thoracic
13
Head & Neck
6
Gastrointestinal
6
Breast
3
CNS
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Dermatologic
1
Classical hematology
1
Conditions
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Interventions
pembrolizumab
100
Nivolumab
69
Cyclophosphamide
67
Ipilimumab
66
fludarabine
34
aldesleukin
29
fludarabine phosphate
28
Vemurafenib
28
Interleukin-2
26
trametinib
20
Biopsy
20
dabrafenib
17
Radiotherapy
16
Temozolomide
15
Cisplatin
15
Magnetic Resonance Spectroscopy
14
Gemcitabine
14
Filgrastim
14
atezolizumab
13
Specimen Handling
13
Carboplatin
13
CTLA-4 Antigen
13
spartalizumab
12
romidepsin
12
Paclitaxel
12
Bortezomib
11
poly ICLC
10
cobimetinib
10
Peripheral Blood Stem Cell Transplantation
10
Oxaliplatin
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Afatinib
×
Dermatologic
×
Clear all
NCT06897735
2026-06-03
EDDIS-a1
Petrov, Andrey
Phase 1
Terminated
4 enrolled